Just Katja Susanne, Steffens Michael, Swen Jesse Joachim, Patrinos George P, Guchelaar Henk-Jan, Stingl Julia Carolin
Research Division, Federal Institute for Drugs and Medical Devices, University Bonn Medical School, Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany.
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Eur J Clin Pharmacol. 2017 Oct;73(10):1247-1252. doi: 10.1007/s00228-017-2292-5. Epub 2017 Jul 2.
Due to the diversity within Europe, the implementation of pharmacogenomic testing in clinical practice faces specific challenges. In the context of the European pharmacogenomics implementation project "Ubiquitous Pharmacogenomics" (U-PGx; funded by the European Commission), we studied the current educational background.
We developed a questionnaire including 29 questions. It was spread out to healthcare professionals working at the future implementation sites (in Austria, Greece, Italy, Netherlands, Slovenia, Spain and Great Britain) of the U-PGx project in preparation of an educational programme. Aim of the survey was to analyse the current educational situation at the implementation sites.
In total, 70 healthcare professionals participated in the survey. Of participants, 84.3% found pharmacogenomics relevant to their current practice, but experience was still rare. More than two-thirds (65.7%) did not order nor recommend a pharmacogenomic test in the past year. This was mainly attributed to not having enough knowledge on pharmacogenomics (40.0%). Needs were identified in application of pharmacogenomics (identifying drugs 41.4%, interpreting test results 37.2%) as well as in underlining mechanisms (better knowledge on drug metabolism 67.1%, better knowledge on basic principles of pharmacogenomics 60.0%).
This study analysed the specific attitudes, experience and education on pharmacogenomics of future users. There was a general positive attitude and interest towards pharmacogenomic testing. However, the grade of own experience, and knowledge about application and interpretation of pharmacogenomics caused uncertainty. Thus, education and training programmes may be helpful for implementation of pharmacogenomics at a homogenous level within Europe.
由于欧洲内部的多样性，临床实践中实施药物基因组学检测面临特定挑战。在欧洲药物基因组学实施项目“泛在药物基因组学”（U-PGx；由欧盟委员会资助）的背景下，我们研究了当前的教育背景。
我们编制了一份包含29个问题的问卷。该问卷分发给了U-PGx项目未来实施地点（奥地利、希腊、意大利、荷兰、斯洛文尼亚、西班牙和英国）的医疗保健专业人员，以筹备一项教育计划。调查目的是分析实施地点当前的教育状况。
共有70名医疗保健专业人员参与了调查。在参与者中，84.3%认为药物基因组学与他们当前的实践相关，但经验仍然很少。超过三分之二（65.7%）的人在过去一年中既没有订购也没有推荐过药物基因组学检测。这主要归因于对药物基因组学缺乏足够的了解（40.0%）。在药物基因组学的应用（识别药物41.4%，解释检测结果37.2%）以及强调机制方面（更好地了解药物代谢67.1%，更好地了解药物基因组学基本原理60.0%）发现了需求。
本研究分析了未来用户对药物基因组学的特定态度、经验和教育情况。对药物基因组学检测普遍持积极态度和兴趣。然而，自身经验的程度以及对药物基因组学应用和解释的了解导致了不确定性。因此，教育和培训计划可能有助于在欧洲范围内以统一水平实施药物基因组学。
